MedTrace Logo

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

NCT06932081 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-02-13

No results posted yet for this study

Summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Conditions

  • Adult Congenital Heart Disease
  • Congenital Heart Disease
  • Systemic Right Ventricle
  • Transposition of the Great Arteries
  • Congenitally Corrected Transposition of the Great Arteries
  • Fontan
  • Single Ventricle
  • Tetralogy of Fallot (TOF)

Interventions

DRUG

SGLT2 inhibitors

Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.

Sponsors & Collaborators

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Anastasia D. Egorova, MD PhD · Leiden University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Netherlands
  • North Macedonia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932081 on ClinicalTrials.gov